The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia
Abstract
Purpose: To study the incidence and prognostic impact of mutations in DNA methyltransferase 3A (DNMT3A) in patients with acute myeloid leukemia. Patients and Methods: A total of 489 patients with AML were examined for mutations in DNMT3A by direct sequencing. The prognostic impact of DNMT3A mutations was evaluated in the context of other clinical prognostic markers and genetic risk factors (cytogenetic risk group; mutations in NPM1, FLT3, CEBPA, IDH1, IDH2, MLL1, NRAS, WT1, and WT1 SNPrs16754; expression levels of BAALC, ERG, EVI1, MLL5, MN1, and WT1). Results: DNMT3A mutations were found in 87 (17.8%) of 489 patients with AML who were younger than 60 years of age. Patients with DNMT3A mutations were older, had higher WBC and platelet counts, more often had a normal karyotype and mutations in NPM1, FLT3, and IDH1 genes, and had higher MLL5 expression levels as compared with patients with wild-type DNMT3A. Mutations in DNMT3A independently predicted a shorter overall survival (OS; hazard ratio [HR], 1.59; 95% CI, 1.15 to 2.21; P = .005) by multivariate analysis, but were not associated with relapse-free survival (RFS) or complete remission (CR) rate when the entire patient cohort was considered. In cytogenetically normal (CN) AML, 27.2% harbored DNMT3A mutations that independently predicted shorter OS (HR = 2.46; 95% CI, 1.58 to 3.83; P < .001) and lower CR rate (OR, 0.42; 95% CI, 0.21 to 0.84; P = .015), but not RFS (P = .32). Within patients with CN-AML, DNMT3A mutations had an unfavorable effect on OS, RFS, and CR rate in NPM1/FLT3-ITD high-risk but not in low-risk patients. Conclusion: DNMT3A mutations are frequent in younger patients with AML and are associated with an unfavorable prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,840
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
ISCN 1995 An international system for human cytogenetic nomenclature
Mitelman, F. (1995) · Cited by 1,930
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Self-citationDNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D., Dunford-Shore, B. H., McGrath, S., Hickenbotham, M., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,422
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Figueroa, M. E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P. J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.020 · Cited by 833
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Marcucci, G., Haferlach, T., & Döhner, H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2554 · Cited by 570
Fröhling, S., Schlenk, R. F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.060 · Cited by 458
Barjesteh van Waalwijk van Doorn-Khosrovani, S. (2003) · Blood · doi:10.1182/blood-2002-05-1459 · Cited by 355
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
Döhner, K., Tobis, K., Ulrich, R., Fröhling, S., Benner, A., Schlenk, R. F., & Döhner, H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.088 · Cited by 322
Dufour, A., Schneider, F., Metzeler, K. H., Hoster, E., Schneider, S., Zellmeier, E., Benthaus, T., Sauerland, M.-C., Berdel, W. E., Büchner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6010 · Cited by 293
Array-based genomic resequencing of human leukemia
Yamashita, Y., Yuan, J., Suetake, I., Suzuki, H., Ishikawa, Y., Choi, Y. L., Ueno, T., Soda, M., Hamada, T., Haruta, H., et al. (2010) · Oncogene · doi:10.1038/onc.2010.117 · Cited by 249
Wagner, K., Damm, F., Göhring, G., Görlich, K., Heuser, M., Schäfer, I., Ottmann, O., Lübbert, M., Heit, W., Kanz, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6899 · Cited by 241
Self-citationHeuser, M., Beutel, G., Krauter, J., Döhner, K., von Neuhoff, N., Schlegelberger, B., & Ganser, A. (2006) · Blood · doi:10.1182/blood-2006-04-014845 · Cited by 232
Self-citationDysregulation of the C/EBPα Differentiation Pathway in Human Cancer
Koschmieder, S., Halmos, B., Levantini, E., & Tenen, D. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9812 · Cited by 212
Schlenk, R. F., Dohner, K., Kneba, M., Gotze, K., Hartmann, F., del Valle, F., Kirchen, H., Koller, E., Fischer, J. T., Bullinger, L., et al. (2009) · Haematologica · doi:10.3324/haematol.13378 · Cited by 210
Marcucci, G., Maharry, K., Whitman, S. P., Vukosavljevic, T., Paschka, P., Langer, C., Mrózek, K., Baldus, C. D., Carroll, A. J., Powell, B. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8720 · Cited by 192
Thol, F., Weissinger, E. M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Gohring, G., Schumann, C., Bug, G., Ottmann, O., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.025494 · Cited by 191
Self-citationPrognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Thol, F., Damm, F., Wagner, K., Göhring, G., Schlegelberger, B., Hoelzer, D., Lübbert, M., Heit, W., Kanz, L., Schlimok, G., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272146 · Cited by 186
Self-citationCensoring distributions as a measure of follow‐up in survival analysis
Korn, E. L. (1986) · Statistics in Medicine · doi:10.1002/sim.4780050306 · Cited by 166
Heuser, M., Argiropoulos, B., Kuchenbauer, F. C., Yung, E., Piper, J., Fung, S., Schlenk, R. F., Döhner, K., Hinrichsen, T., Rudolph, C., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080523 · Cited by 164
Self-citationDamm, F., Heuser, M., Morgan, M. A., Yun, H., Großhennig, A., Göhring, G., Schlegelberger, B., Döhner, K., Ottmann, O. G., Lübbert, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0342 · Cited by 128
Self-citationIntegrative prognostic risk score in acute myeloid leukemia with normal karyotype
Damm, F., Heuser, M., Morgan, M. A., Wagner, K., Görlich, K., Großhennig, A., Hamwi, I., Thol, F. R., Surdziel, E., Fiedler, W., et al. (2011) · Blood · doi:10.1182/blood-2010-08-303479 · Cited by 112
Self-citationBaldus, C. D., Martus, P., Burmeister, T., Schwartz, S., Gökbuget, N., Bloomfield, C. D., Hoelzer, D. F., Thiel, E., & Hofmann, W. K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5253 · Cited by 100
Self-citationGene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.
Heuser, M., Wingen, L. U., Steinemann, D., Cario, G., Neuhoff, N. V., Tauscher, M., Bullinger, L., Krauter, J., Heil, G., Döhner, H., et al. (2005) · PubMed · Cited by 84
Self-citationPrognostic Importance of Histone MethyltransferaseMLL5Expression in Acute Myeloid Leukemia
Damm, F., Oberacker, T., Thol, F. R., Surdziel, E., Wagner, K., Chaturvedi, A., Morgan, M. A., Bomm, K., Göhring, G., Lübbert, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1118 · Cited by 55
Self-citation
Cited by
Acute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
The role of mutations in epigenetic regulators in myeloid malignancies
Shih, A. H., Abdel-Wahab, O., Patel, J. P., & Levine, R. L. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3343 · Cited by 611
Creutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., et al. (2012) · Blood · doi:10.1182/blood-2012-03-362608 · Cited by 577
DNMT3A in haematological malignancies
Yang, L., Rau, R., & Goodell, M. A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3895 · Cited by 509
Russler-Germain, D. A., Spencer, D. H., Young, M. A., Lamprecht, T. L., Miller, C. A., Fulton, R., Meyer, M. R., Erdmann-Gilmore, P., Townsend, R. R., Wilson, R. K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.010 · Cited by 452
Metadata
- Authors
- Thol, F., Damm, F., Lüdeking, A., Winschel, C., Wagner, K., Morgan, M., Yun, H., Göhring, G., Schlegelberger, B., Hoelzer, D., Lübbert, M., Kanz, L., Fiedler, W., Kirchner, H., Heil, G., Krauter, J., Ganser, A., & Heuser, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-07-20
- Volume
- 29
- Issue
- 21
- Pages
- 2889-2896
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2109554035
- Cited by
- 374
- References
- 33
- FWCI
- 28.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.